Evidence for Specific sites in fibrin(ogen) that stimulate tissue activator catalyzed plasminogen activation

Chapters in this book

1. Frontmatter I
2. Preface V
3. Contributors And Addresses VII
4. Contents XIII
5. I. Physicochemical Aspects
6. Hydrodynamic characterization of human fibrinogen 3
7. Early plasmin digestion of fibrinogen: light scattering data 19
8. Correlation of fibrinopeptide A release and light scattering during fibrinogen to fibrin transformation 25
9. A kinetic approach to the polymerization of fibrin at high ionic strength 31
10. Secondary Structure Of Fibrin 37
11. II. Fibrinogen-Fibrin Conversion
12. Synthetic peptide Gly-His-Arg-Pro activates fibrin monomers 49
13. Fibrinopeptide characterization and kinetics of release in animal fibrinogens as analysed by highperformance liquid chromatography 59
14. III. Interaction with Divalent Cations
15. The topography of fibrinogen fragment D 73
16. Calcium binding to fibrinogen investigated by rate of dialysis 85
17. Calcium-binding sites and anticlotting properties of human fibrinogen and fibrin(ogen) fragments 97
18. Binding of fibrinogen and degradation products to chelated zinc 111
19. IV. Abnormal Fibrinogens
20. Genetically abnormal fibrinogens - some current characterisation strategies 125
21. Two-dimensional electrophoretic characterization (iso-dalt) of fibrinogen and fibrin subunit chains from four different genetic dysfibrinogen variants 145
22. The molecular abnormality of fibrinogen Manchester 155
23. Functional characterisation and protein chemical analysis of two new cases of dysfibrinogenemia, London III & IV 167
24. Genetically abnormal fibrinogens releasing abnormal fibrinopeptides as characterised by high-performance liquid chromatography 183
25. Sialic acid and sialyltransferase in the pathogenesis of acquired dysfibrinogenaemia 195
26. V. Fibrinogen Derived Products in vitro and in vivo
27. Comparative studies on F-CB3 related antigen, fibrinogen degradation products, soluble fibrin monomer complexes and fibrinogen in patients with renal carcinoma 209
28. Characterization of crosslinked high molecular weight fibrin derivatives from in vitro and in vivo (ascitic fluid) material 215
29. Immunochemical differentiation of fibrinogen, fragment D or E, and cross-linked fibrin degradation products using monoclonal antibodies 227
30. Purification and properties of early (X-like) and late (D-like) fibrinogen fragments, produced by leukocyte elastase 235
31. Formation of fibrin degradation products from a non-anticoagulated whole blood clot 255
32. VI. Biosynthesis and Clearance
33. Changes of synthesis of fibrinogen polypeptide and albumin mRNAs in rat liver after turpentine injection and after partial hepatectomy or laparotomy 263
34. Role of kidney in eliminating low molecular weight fibrinogen derivatives from the circulation 279
35. Clearance of I¹²⁵ fibrinogen and I¹³¹soluble fibrin in normals and in fibrinaemic patients: a pilot study 287
36. Clearance of homologous fibrin monomers and fibrin(ogen) degradation products in the rat 291
37. VII. Other Physiological Aspects of Fibrinogen
38. Evidence for Specific sites in fibrin(ogen) that stimulate tissue activator catalyzed plasminogen activation 305
39. Vasoactive Peptides Released From The ßß-Chain On Degradation Of Human Fibrin(Ogen) By Plasmin Or Elastase 315
40. Interactions between fibrin and fibronectin. No effect of fibronectin on the plasma solubility of fibrin monomers 323
41. Interactions between fibronectin and soluble fibrin - no effect of fibrin monomers upon the formation of the heparin precipitable fraction of plasma 329
42. Author Index 337
43. Subject Index 339
44. Backmatter 344